Elizabeth Docteur Deputy Head, Health Division Organization for Economic Cooperation and Development Visit to the Korean Ministry of Health and Welfare.

Slides:



Advertisements
Similar presentations
1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
Advertisements

Differential Pricing: Reconciling R&D, IP and Access Patricia M. Danzon PhD The Wharton School University of Pennsylvania.
Gender Perspectives in Introduction to Tariffs Gender Module #5 ITU Workshops on Sustainability in Telecommunication Through Gender & Social Equality.
OECD Pension Fund Portfolio Allocation mr.sc. Tomislav Petrov.
Pricing and Reimbursement Policies 27. Pricing Policies Patented Medicines Patented Medicine Prices Review Board (PMPRB) monitors and sets the price of.
Quaker Council for European Affairs – A Quaker Voice in Europe The European Union Budget Overview and Income.
Role of Pharmacoeconomics in a Developing country context Gavin Steel for Anban Pillay Cluster Manager: Health Economics National Department of Health.
Reimbursement & Pricing in Turkey
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
1 “European R&D Benchmarking (2002) “European R&D Benchmarking (2002)” Science, Technology and Innovation Policy Student Presentations Students: Miguel.
The Pharmaceutical Industry in Europe Key data INDUSTRY (EFPIA Total) (*) Production63,127121,311158,647170,000 (e) Exports23,18089,443144,022170,000.
OECD World Forum “Statistics, Knowledge and Policy”, Palermo, November Territorial Indicators for Regional Policies Vincenzo Spiezia Head,
Healthcare Reform in China and Its Impact on the Pharmaceutical Industry Hengpeng Zhu Institute of Economics Chinese Academy of Social Sciences
How is the budget raised The own resource system – The overall amount of own resources needed to finance the budget is determined by total expenditure.
Pricing and Reimbursement Policies 1. Pricing Policies Patented Medicines Maximum retail prices capped by Ministry of Economy (mainly for private sector)
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
The measurement of Innovation An historical perspective The “Frascati Manual” and the “Oslo Manual” S&T indicators Innovation indicators Some evidence.
1 WHO/HAI Pricing Policy Papers To assist policy-makers and others, WHO and HAI are developing a series of reviews on pharmaceutical pricing policies and.
Michelle Boudreau, Executive Director Pricing and Reimbursement Toronto, Ontario June 11, 2012 Patented Medicines Prices Review Board (PMPRB): 25 Years.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Health Care Reform Quynh Smith. Sources of Inefficiency in the Health Care Delivery System   We spend a substantial amount on high cost, low-value treatments.
Approaches to Pharmaceutical Regulation in Europe and the USA Panos Kanavos London School of Economics Washington, D.C., 10 June 2003.
Health care reform in the Netherlands – role of the employer
CH 1. Factors accounting for the growth of importance in the health sector  Global health and longevity gains  Expansion of health sector throughout.
Lukas Steinmann Mexico 10. June 2008 To your health: diagnosing the state of healthcare and the global private medical insurance industry.
The Czech Health System – its Presence and Future Pavel Hroboň L.Dittrich.
Universal Health Coverage: The Canadian Experience PAHO Working Group on Universal Health Coverage Washington D.C. August 18-20, 2014.
The Economic Impact of Pharmaceutical Parallel Trade: A Stakeholder Analysis Panos Kanavos, PhD London School of Economics, UK AcademyHealth, San Diego,
HTA Regulation and Economic Evaluation in Europe: where are we? Professor Alistair McGuire, LSE, London Istanbul, May 2009.
Universal Pharmacare: Solving Canada’s Drug Problem Pharmacare Forum Windsor Public Library, April 26, 2011 Canadian Health Coalition.
The Pharmaceutical Industry in Turkey
Drug Prices in Canada and the US: More Than Meets the Eye? National Academy of Social Insurance Annual Conference Wayne Critchley Executive Director, PMPRB.
TBS Seminar on Essential Medicines and Health Products Geneva, 29 October 2013 Matthew Jowett, PhD Senior Health Financing Specialist Dept. Health Systems.
The Role of the Fiscal Policy in Poverty Reduction Youngsun Koh Korea Development Institute.
EXPERIENCES IN SOUTH AFRICA WITH THE INTRODUCTION OF PHARMACEUTICAL PRICING LEGISLATION Zokufa HZ, Pillay T Pharmaceutical Policy and Planning, Department.
Potentials for drug savings in the generic sector - experience accross Europe" Per Troein Vice President Strategic Alliances IMS Health.
Competitiveness of the European-based Pharmaceutical Industry Prospective of a New Member State Imre Hollo Deputy Secretary of State, MOH Hungary.
PETER GONDA Conservative Institute of M.R. Štefánik, Member of Socia Fdn., SLOVAKIA Financing of Long Term Care in Slovakia: Comparison with other OECD.
1 Private Health Insurance in the OECD The OECD Health Project Francesca Colombo, OECD Gastain, 7 October 2004
Title text here Consumer Perspective on Containing Drug Costs Leigh Purvis, Director, Health Services Research.
The Economic Impact of Pharmaceutical Parallel Trade in Europe Panos Kanavos, PhD London School of Economics & Political Science, London, UK FDA oral testimony.
Ian D. Spatz Merck & Co., Inc. January 14, 2004 Ian D. Spatz Merck & Co., Inc. January 14, 2004 Overview of the New Medicare Prescription Drug Law.
IPSG Expert Meeting – Customer Satisfaction Mapping 1st December 2005.
1 Medicare Reform: Implications for Pharmaceutical Manufacturers G. Lawrence Atkins, PhD Schering-Plough Corporation January 14, 2004.
International Comparison of Health Care Gene Chang.
1 Practical Challenges on the Medicine pricing Regulations Presentation to the Portfolio Committee on Health By the National Department of Health 16 November.
Zokufa HZ, Pillay T Pharmaceutical Policy and Planning National Department of Health- South Africa.
Funding health care: current options and future direction Anna Dixon Research Officer.
The Euro Area Crisis: Origins, Prospects and Implications for the World Economy and Global Governance Domenico Lombardi UNLV, April 3, 2013.
MEDICARE PART D July MEDICARE PART D: OVERVIEW Part D provides prescription drug coverage for Medicare beneficiaries. Prescription drug plans compete.
Private Health Insurance
Political Economics Riccardo Puglisi Lecture 4 Content: Welfare State: Facts, Data and Relevant Issues Economic Policies Size and Composition of the Welfare.
Pharmacy Benefit Management (PBM) 101
Fixed Book Prices – an international perspective Richard Charkin IPA President Brasilia 30 June 2015.
Modernizing Health Care Inez Bartels.  Strong focus on the provision of health care  Institutions governing health care consumption control patients.
Medicaid Influence in the Drug Market Dana Costea PhD student, Department of Economics, Lehigh University Franklin Carter Assistant Professor, Marketing.
Recent reforms in decentralization frameworks in OECD countries: financial, institutional and territorial aspects Joaquim OLIVEIRA MARTINS Head, OECD Regional.
PHARMACEUTICAL PRICING POLICY PROJECT Executive Summary and Conclusions Valérie Paris Warsaw 19 March 2008.
Health Policy Issues An Economic Perspective Copyright © 2015 Foundation of the American College of Healthcare Executives. Not for sale.
The pharmaceutical market in Europe
1  Energy efficiency has led to a decoupling of economic and energy growth.  In 2013, OECD energy consumption = 2000 levels, while GDP expanded by 26%.
Economics of Pharmaceutical Regulation in the Mediterranean: the case of Spain and Italy Joan Costa Font LSE.
The Global Market for Pharmaceuticals and Policy Responses
The Czech Health System – its Presence and Future
Free Trade and Intellectual Property Rights: Implications for the Canadian Pharmaceutical Environment Joel Lexchin MD School of Health Policy & Management.
Roberto ASTOLFI and Luca LORENZONI
The Economic Impact of Pharmaceutical Parallel Trade in Europe
The U.S. Health Care System: An International Perspective
National Trends in Per Capita Pharmaceutical Spending, 1980–2015
National Pharmacare in Canada: Choosing a Path Forward
Presentation transcript:

Elizabeth Docteur Deputy Head, Health Division Organization for Economic Cooperation and Development Visit to the Korean Ministry of Health and Welfare May 9, 2007 The Global Market for Pharmaceuticals and Policy Responses

2 Overview Pharmaceutical sales and sellers Pharmaceutical expenditures and purchasers Pharmaceutical price regulation Concluding remarks

3 US Dominates Global Market in Retail Pharmacy Drug Purchases

4 10 corporations account for half of global sales TOP CORPORATIONS BY GLOBAL PHARMA SALES IN % GROWTH GLOBAL SALES CONSTANT $ % GLOBAL CAGR > RANKING US$ BN SALES Pfizer GlaxoSmithKline Sanofi -Aventis Novartis Johnson & Johnson AstraZeneca Merck & Co Roche Abbott Bristol-Myers Squibb TOTAL Top 10 Corporations $ Source IMS, Intelligence 360, IMS Health MIDAS, Dec 2005

5 Global pharmaceutical sales have increased % annually since 1998

6 Sales growth factors: Changing importance of volume/mix, new products and price

7 Growth factors vary across countries, 2004 SOURCE: IMS Health Data MIDAS MAT Dec 2004

8 Cross-European price differentials are diminishing

9 Wide variation in share of generics in the pharmaceutical market, 2004 Volume 37% USA 35%Canada 33%UK 30%Germany 10%France 8% Spain 4%Italy 2%Japan Value 7% 16% 19% 20% 7% 5% 4% 2% SOURCE: IMS Health MIDAS, MAT Dec 2004

10 Determinants of pharmaceutical sales value SALES = [Ex-manufacturer Price] x [Volume of units sold] Where volume over a product’s life cycle is a function of: Total time on market Extent of competition (from generics, therapeutic alternatives) Prescribing regulations and practice patterns Coverage by insurance Financial incentives faced by doctors, pharmacists and patients Advertising/marketing Thus, a range of policy levers exist by which to affect pharmaceutical sales and industry profits, including: Marketing authorization practices Default coverage status: positive lists (formularies) versus negative lists Physician prescribing and dispensing policies Patient cost-sharing (co-payments, deductibles) Pharmaceutical pricing and reimbursement pricing policies and practices are just part of a bigger picture

11 Variation in availability of new drugs Time between first launch in the world and first launch in the country for drugs launched between 1999 and 2002

12 Average time between receipt of marketing authorization and launch on market Belgium Greece Portugal France Austria Finland Italy Norway Spain Netherlands Switzerland Sweden Denmark Ireland Germany UK (Days) Increasing overall delay P&R PricingReimbursement Publication 180 days90 days Source: WHO Priority Medicines for Europe and the World Project, 2004.

13 Drug expenditure per capita (public and private) in OECD countries, 2004 (1) 2003; (2) 2002 OECD Health Data 2006

14 Real annual growth in pharmaceutical spending and total health expenditure (net of pharmaceutical expenditure) in the OECD, (1) ; (2) ; (3) ; (4) OECD Health Data 2006

15 Drug expenditure as share of total health spending and share of GDP in OECD countries, 2004 (1) 2003 (2) 2002 SOURCE: OECD Health Data 2006

16 Determinants of pharmaceutical expenditure Expenditure = [volume of units sold] x [retail price] Where retail price = [Ex-manufacturer price] + [distributor/wholesale mark-up] + [retail mark-up] + [VAT or sales tax paid by consumer] Variation across OECD countries is very large For example, the share of the retail price accruing the product manufacturer ranges across Europe from a low of 45% to a high of 88% Many countries have scope to relieve the burden on public and private financing for pharmaceuticals by obtaining efficiencies in the supply chain.

17 Policy framework for pharmaceutical pricing and reimbursement Pharmaceutical sectors reflect a mix of policies –free pricing --- in which prices are set according to what the market will bear, without government intervention –regulated pricing --- in which prices are defined or capped according to government rules –reimbursement pricing --- in which purchasers establish the level of subsidies paid for pharmaceutical products. In the case of public purchasers, reimbursement pricing may reflect the use of regulatory authority in addition to purchasing power. –de facto price regulation --- in which purchasers establish the level of subsidies paid for pharmaceutical products and set limits on how much patients can be charged above the reimbursement level. Objectives –Free pricing seeks to optimize efficiency through market competition –Price regulation seeks to provide some degree of consumer protection against the risk that manufacturers will exploit their market power to charge excessive prices for goods considered essential –Reimbursement pricing generally seeks to promote accessibility and affordability of pharmaceuticals via subsidies –de facto price regulation seeks to meet both objectives

18 Approaches used to set prices Prices subject to price-setting vary and include –Ex-manufacturer price –Retail price –Reimbursement price Methods and considerations in price setting –Internal price referencing (therapeutic benchmarking) –External price referencing (international benchmarking) –Cost-effectiveness assessment –Consideration of budget impact –Negotiations with manufacturers (which may include agreements for risk-sharing, rebates or discounts) –Profit control –Consideration of manufacturer costs (R&D, production)

19 Overview of pharmaceutical pricing in 6 OECD countries Free pricing –In Germany, all pharmaceutical products. –In Canada, all off-patent pharmaceuticals. –In Mexico, all off-patent pharmaceuticals, as well as on-patent products sold to public purchasers. –In both Sweden and Switzerland, any pharmaceutical product that has received approval for marketing that is not reimbursed by the universal health coverage scheme. –In Slovakia, no pharmaceutical products. Price regulation –In Slovakia, prices of all pharmaceutical products are regulated: retail prices for medicines sold outside hospital and ex-manufacturer prices for hospital drugs. –In Canada, all on-patent pharmaceuticals sold in Canada, to any purchaser. Regulation defines a level which ex-manufacturer price may not exceed. –In Mexico, any on-patent pharmaceuticals sold in the private market. Regulation defines maximum retail price paid by consumers. Participation in pricing scheme is voluntary. –In Sweden, Switzerland, and Germany there is no formal price regulation.

20 Preliminary findings from six case studies (cont’d) Reimbursement pricing arrangements –Sweden, Switzerland and Slovakia have universal coverage through a common scheme –Germany has universal coverage through a common scheme for 90% of the population; 10% opt out and use private coverage –In Canada, employment-based private insurance predominates. Vulnerable populations are often covered through provincial, territorial and federal schemes. Significant diversity in coverage arrangements. –Half of Mexicans have drug coverage through various social insurance schemes; half have no coverage but may be eligible for drugs furnished through federal programmes. Most Mexicans buy drugs at retail prices with no reimbursement. de facto price regulation –In Sweden and Switzerland, prices paid for drugs reimbursed by the universal health coverage schemes’ (quite inclusive) positive lists are regulated. There is a limit on what manufacturers can charge for reimbursed drugs. –In Germany, there is no limit on prices charged by manufacturers, even for reimbursed drugs. (Neither direct nor de facto regulation). –Canada, Mexico and Slovakia use direct price regulation.

21 Overview of preliminary findings (cont’d) Cost-sharing arrangements vary widely –In Sweden, a graduated cost-sharing formula is used with an annual cap on total out-of-pocket (OOP) spending. –In Switzerland, a cost-sharing formula exists for all drugs reimbursed by basic insurance. Private insurance is prohibited from covering cost-sharing amounts. –In German social insurance, co-payments are set at 10% of the drugs’ reimbursement price, with a minimum of €5 and a maximum of €10. Patients must pay out-of-pocket any difference between the retail price and the reimbursement price. Caps on OOP of 1% or 2% of income apply. –In Slovakia, cost-sharing is set as a share of the reimbursed price. The ratio is maintained even if manufacturer lowers price. There is no cap on OOP. –In Canada, cost-sharing arrangements vary widely. –In Mexico, there is no cost-sharing for prescription drugs included in the public schemes’ formularies and dispensed through public pharmacies, although drugs are not always available and there are perceived quality issues.

22 Methods used to set prices Internal reference pricing –Used in price regulation in Canada. Prices of ‘me-too’ drugs and drugs offering little or no therapeutic improvement cannot exceed price of comparable products –Used in reimbursement pricing in Germany, Slovakia and Switzerland, and in some Canadian provinces In Switzerland, price of alternatives in therapeutic class considered (with flexibility) in reimbursement price negotiations. Particularly innovative drugs may be awarded an “innovation bonus.” New generics must have lower reimbursement price than the original product or existing generics. In Germany, reimbursement price is defined for reference group consisting of at least 3 drugs. Drugs may be sold at prices above the reference price in theory, but rarely in practice. In Slovakia, internal reference pricing is used to create reference price determining reimbursement price. Drugs may be (and are) sold at prices above the reference price. –Not used in Sweden and Mexico

23 Methods used to set prices (cont’d) External reference pricing –Used in price regulation in Canada, Mexico and Slovakia Median price in seven comparator countries, selected because of their support for domestic pharmaceutical industry, considered as cap for ex-manufacturer prices of breakthrough drugs in Canada Weighted average price of six countries with highest sales penetration for a particular product serves as reference for defining maximum retail price in Mexico Median ex-manufacturer price in nine countries considered when setting retail price in Slovakia. –Used in de facto price regulation in Switzerland Average price of four economically comparable countries plus three alternates considered as Swiss reimbursement price cap (much flexibility) –Not used in Germany or Sweden

24 Methods used to set prices (cont’d) Cost-effectiveness analysis –Used in price regulation in Canada and Slovakia In Canada, drugs that offer significant savings, in comparison with therapeutic alternatives, can be classed as “substantial improvements,” with price caps determined by international benchmarks (rather than therapeutic alternatives). –Used in reimbursement pricing in Canada and Sweden and --- to a lesser extent --- in Mexico and Switzerland In Canada, CE is a very strong consideration in national, non-binding reimbursement recommendations for publicly financed drug coverage schemes. Also considered in formulary decisions by public plans. In Sweden, CE from social perspective is most important consideration in formulary inclusion and reimbursement pricing decisions. In Mexico, CE is considered to some extent by public coverage schemes in formulary inclusion decisions. In Switzerland, CE not formally considered in formulary and reimbursement pricing, but manufacturers may supply info and use in price negotiations. –Not used in Germany at present

25 Other factors in pharmaceutical pricing Cost or budgetary considerations –Considered in formulary inclusion decisions in Canada and Mexico. –Not taken into account in reimbursement pricing or coverage decisions in Germany, Slovakia, Sweden and Switzerland. –Germany sometimes requires discounts to public purchasers. Distribution costs –Wholesale and/or retail margins are fixed in Germany, Slovakia, Sweden and Switzerland. –In Canada, both public and private third-party payers define mark- ups and other similar types of regulation. –Wholesale and/or retail margins are implicitly determined in Mexico by manufacturers who set both the ex-manufacturer and maximum retail sales price.

26 Summary and conclusions The global pharmaceutical market is large and growing Market value is not just about price levels –Many relevant market factors and policy levers Manufacturers operate in a global market, where policies and outcomes in one country bear on what happens elsewhere The United States is the most important pharmaceutical market –The US accounts for 1/3 of global retail pharmaceutical sales and is responsible for 40% of all non-hospital drug expenditures in the OECD. –The US is characterized by relatively high prices for patented medicines, and quick uptake and diffusion of new products. –Only a few other markets share this combination of characteristics, which contribute to high sales and profits for the research-based pharmaceutical industry, but no other market compares to the US in size. –Changes that affect the US prices obtained by manufacturers and/or the level or mix of consumption have significant implications for the industry as a whole.

27 Summary and conclusions (cont’d) Pharmaceutical policies in OECD countries vary widely These schemes have different objectives, apply different approaches and achieve different outcomes The notion of regulated/free market pricing is overly simplistic and does not reflect the reality of the policy responses

28 More information Project web page: OECD Health Working Papers can be downloaded at no charge: –“Pharmaceutical Pricing and Reimbursement Policies in Canada,” OECD Health Working Paper #24. –“Pharmaceutical Pricing and Reimbursement Policies in Mexico,” OECD Health Working Paper #25. –“Pharmaceutical Pricing and Reimbursement Policies in Switzerland,” (forthcoming). –“Pharmaceutical Pricing and Reimbursement Policies in Sweden,” (forthcoming). –“Pharmaceutical Pricing and Reimbursement Policies in Germany,” OECD Health Working Paper (forthcoming). –“Pharmaceutical Pricing and Reimbursement Policies in Slovakia,” OECD Health Working Paper (forthcoming).